KALA BIO, Inc.
KALA • NASDAQ
KALA BIO, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO David Elliot Lazar, with a market cap of $11.1M.
CEODavid Elliot Lazar
Market Cap$11.1M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees43.0
Websitekalarx.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for KALA BIO, Inc.
Date
Monday, March 30, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.77
Earnings History
Past 12 earnings reports for KALA BIO, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | Q3 2025 | -$1.07Est: -$1.36 | +21.3% | - | — |  10-Q |
| Aug 8, 2025 | Q2 2025 | -$1.71Est: -$1.95 | +12.3% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$1.41Est: -$2.54 | +44.5% | - | — | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$1.74Est: -$2.28 | +23.7% | - | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$1.93Est: -$2.43 | +20.6% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$3.16Est: -$4.40 | +28.2% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$4.20Est: -$2.89 | -45.3% | - | — | 10-Q |
| Mar 29, 2024 | Q4 2023 | -$3.18Est: -$3.62 | +12.2% | - | — | 10-K |
| Nov 13, 2023 | Q3 2023 | -$3.41Est: -$2.15 | -58.6% | -Est: $830.0K | -100.0% | — |
| Aug 4, 2023 | Q2 2023 | -$4.36Est: -$3.19 | -36.7% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$6.99Est: -$4.52 | -54.6% | - | — | 10-Q |
| Mar 3, 2023 | Q4 2022 | -$6.46Est: -$6.55 | +1.4% | - | — | — |